Research Topics
Genomes and GenesSpecies | Thierry PoynardSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirinThierry Poynard
Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
Hepatology 38:481-92. 2003..In conclusion, these biochemical markers of fibrosis and activity could be used as surrogate markers for liver biopsy in patients with chronic hepatitis C, both for the initial evaluation and for follow-up...
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver diseaseThierry Poynard
Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
BMC Gastroenterol 6:34. 2006..The aim was to develop and validate a new biomarker of non alcoholic steato hepatitis (NASH) the NashTest (NT) in patients with NAFLD...
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver diseaseVlad Ratziu
Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
BMC Gastroenterol 6:6. 2006..The aim of this study was to determine the diagnostic utility of non-invasive markers of fibrosis, validated in chronic viral hepatitis and alcoholic liver disease (FibroTest, FT), in patients with NAFLD...
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis CYen Ngo
, , CNRS, Paris, France
Clin Chem 52:1887-96. 2006..001) in multivariate analyses after taking into account histology, treatment, alcohol consumption, and HIV coinfection. CONCLUSION: The FibroTest measurement of HCV biomarkers has a 5-year prognostic value similar to that of liver biopsy...
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donorsFrancoise Imbert-Bismut
Service of Biochemistry, hôpital La Pitié Salpêtrière, Paris, France
Clin Chem Lab Med 42:323-33. 2004..075+/-0.004 and 0.068+/-0.004, respectively. The low intra-laboratory and intra-patient variability in Fibrotest and Actitest results confirm Fibrotest and Actitest reliability...
Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patientsPatrick Ingiliz
Hepatology Department, Pitie Salpetriere Hospital, Paris, France
Antivir Ther 13:895-900. 2008..Adefovir dipivoxil (ADV) has shown its efficacy for treating 3TC-resistant (3TC-R) HBV in HIV-coinfected patients. ADV combined with pegylated interferon (PEG-IFN) has never been evaluated in this population...
Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapyRobert P Myers
Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
AIDS 18:75-9. 2004..Pegylated interferon alpha (PEG-IFN-alpha) and ribavirin is the most effective available treatment for chronic hepatitis C virus (HCV) infection. Its role in HIV/HCV-co-infected patients who have failed IFN-based therapy is unclear...
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?Dominique Thabut
Services d Hépato gastroentérologie, Group Hospitalier Pitié Salpêtrièe, Paris, France
Am J Gastroenterol 101:1260-7. 2006....
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studiesThierry Poynard
University Pierre and Marie Curie Liver Center, Paris, France
Antivir Ther 15:617-31. 2010..We aimed to review evidence-based published data of biomarkers that have been validated as non-invasive alternatives to biopsy as end points for HBV and HCV infection trials...
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ programThierry Poynard
APHP UPMC Liver Center, Paris, France
J Hepatol 54:227-35. 2011....
Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of ageThierry Poynard
APHP UPMC Paris Liver Center, Paris, France
BMC Gastroenterol 11:39. 2011..The aims were to estimate the prevalence of RFPN and of proven failures, and to identify factors associated with their occurrences...
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)Thierry Poynard
APHP UPMC Liver Center, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Paris, France
BMC Gastroenterol 10:40. 2010..One challenge was to use them for estimating the prevalence of fibrosis, identifying independent risk factors and to propose screening strategies in the general population...
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis BRobert P Myers
Department of Hepatology and Gastroenterology, , Paris, France
J Hepatol 39:222-30. 2003..CONCLUSIONS: The aminotransferases and an index including five biochemical markers are accurate noninvasive markers of HBV-related activity and fibrosis, respectively...
Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetesSophie Jacqueminet
Service de Diabetologie, APHP GHPS, Paris, France
Clin Gastroenterol Hepatol 6:828-31. 2008..We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) in patients with diabetes...
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral loadYen Ngo
Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS UMR 8149, Paris, France
PLoS ONE 3:e2573. 2008..We compared the 4-year prognostic value of combining FT-AT and viral load for a better definition of the inactive carrier status...
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patientsRobert P Myers
Department of Hepatology and Gastroenterology, , Paris, France
AIDS 17:721-5. 2003..CONCLUSION: An index including five biochemical markers accurately predicts significant fibrosis in patients with HIV/HCV co-infection, and may substantially reduce the necessity for liver biopsy...
Viral hepatitis CThierry Poynard
Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Universite, Paris, France
Lancet 362:2095-100. 2003..These antiviral treatments reduce liver fibrosis progression and can reverse cirrhosis. Unfortunately, even in developed countries, death due to hepatitis C is increasing because of inadequate detection and treatment...
Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysisPatrick Ingiliz
Hepatology Department, Pitie Salpetriere Hospital, Paris, France
J Hepatol 56:49-54. 2012..The course of the disease is determined by the rapidity of liver fibrosis progression (LFP). The influence of interferon on LFP in coinfected patients has yet not been evaluated by comparative liver biopsies...
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis CThierry Poynard
Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
Clin Chem 50:1344-55. 2004....
Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis BDominique Thabut
Hepato Gastroenterology Unit, Hopital Pitie Salpetriere, Paris, France
Eur J Gastroenterol Hepatol 16:1367-73. 2004..The clinical features, course and viral mutations associated with the emergence of viral resistance in this population have not been well studied...
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trialLaetitia Fartoux
AP HP, Hopital Saint Antoine, Paris, France
Clin Gastroenterol Hepatol 5:502-7. 2007..We designed a randomized controlled trial comparing the efficacy of prolonged IFN alfa-2a treatment vs nontreatment on complication-free survival in patients with compensated HCV cirrhosis...
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II studySamy Louafi
Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
Cancer 109:1384-90. 2007..In a Phase II trial involving previously untreated patients with advanced HCC, the more favorable schedule from a previous pilot study was evaluated...
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experienceMona Munteanu
Biopredictive, , 47-83 Boulevard de l'Hopital, Paris, France
J Gastrointestin Liver Dis 17:187-91. 2008
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markersThierry Poynard
APHP Groupe Hospitalier Pitié Salpétrière, Universite Paris VI, CNRS UMR, Paris, France
PLoS ONE 3:e3857. 2008..The aim was to identify factors associated with LSM accuracy using FT as a non-invasive endpoint and vice versa...
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosisThierry Poynard
Assistance Publique Hopitaux de Paris, Université Pierre et Marie Curie Liver Center, Paris, France
Clin Gastroenterol Hepatol 10:657-63.e7. 2012..We investigated whether this controversy results from limitations of biopsy analysis for intermediate-stage fibrosis and inappropriate determination of the standard area under the receiver-operator characteristic curve (AUROC)...
The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumptionFrancoise Imbert-Bismut
Department of Biochemistry, APHP Groupe Hospitalier Pitié Salpétrière, Paris, France
Eur J Gastroenterol Hepatol 21:18-27. 2009..The aim was to improve the accuracy of the percentage of CDT by taking into account the presence of fibrosis and steatosis, estimated using biomarkers FibroTest and SteatoTest...
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovirOlivier Lada
Virology, AP-HP Pitie-Salpetriere Hospital, Paris, France
Antivir Ther 9:353-63. 2004..The excellent activity of TDF on lamivudine-resistant virus independently of the resistance mutation profile offers an interesting treatment alternative to HIV-HBV coinfected patients...
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapyThierry Poynard
Service d Hepatologie, Université Pierre et Marie Curie Liver Center, hôpital La Pitié Salpêtrière, Paris, France
Gastroenterology 136:1618-28.e2. 2009..Alternate options are needed for patients who relapse or do not respond to therapy...
Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitisBenjamin Terrier
Department of Internal Medicine, Universite Pierre et Marie Curie, Paris, France
J Hepatol 55:756-61. 2011..Data are lacking in HIV-HCV coinfected patients...
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stagesThierry Poynard
Assistance Publique Hôpitaux de Paris Groupe Hospitalier Pitié Salpêtrière, Paris, France
Clin Chem 53:1615-22. 2007..The aim of this study was to assess the relationships between the AUC and the prevalence of each fibrosis stage and to elaborate simple methods of standardization...
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1Yves Benhamou
Groupe Hospitalier Pitie Salpetriere, Service de d Hépato Gastroentérologie, Paris, France
J Hepatol 44:62-7. 2006..Adefovir dipivoxil (10 mg once-daily) was added to antiretroviral therapy including lamivudine in 35 HIV/HBV co-infected patients...
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infectionThierry Poynard
Department of Hepatology and Gastroenterology, , Paris, France
Am J Gastroenterol 100:1970-80. 2005..FT-AT should be useful in the noninvasive follow-up of lamivudine treatment...
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 studyAmani Asnacios
Department of Hepato gastro enterology, Pitie Salpetriere Hospital, Paris, France
Cancer 112:2733-9. 2008....
Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infectionNadia Alatrakchi
Laboratoire d'Immunologie Cellulaire et Tissulaire INSERM U543, , Paris, France
AIDS 18:121-3. 2004..This suggests that IFN+R therapy might compromise virus-specific immune defenses in immunosuppressed patients...
Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet indexRobert P Myers
Department of Gastroenterology and Hepatology, , Paris, France
Dig Dis Sci 48:146-53. 2003..In conclusion, an index of five biochemical markers accurately predicts significant hepatitis C-related fibrosis and is superior to traditional markers...
Treatment of cirrhotic patients in the pegylated interferon eraThierry Poynard
Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
Dig Liver Dis 36:S344-8. 2004..Non-invasive biochemical markers of liver fibrosis should facilitate the management...
Sampling variability of liver biopsy in nonalcoholic fatty liver diseaseVlad Ratziu
Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
Gastroenterology 128:1898-906. 2005..The aim of this study was to assess the sampling error of liver biopsy and its impact on the diagnosis and staging of NASH...
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient dataThierry Poynard
APHP UPMC Liver Center, Paris, France
PLoS ONE 7:e30325. 2012..The aim of this study was to perform an overview of 3 studies which assessed the performance of non-invasive markers of fibrosis (FibroTest), steatosis (SteatoTest) and steato-hepatitis (NashTest, ActiTest) in these patients...
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large populationThierry Poynard
APHP UPMC Paris Liver Center, Paris, France
J Hepatol 57:541-8. 2012..We aimed at validating this concept by comparing LFP using FT vs. biopsy (P1) and then at applying the non-invasive method to a large population (P2)...
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapyPatrick Ingiliz
Hepatology Department, AP HP, GH Pitié Salpétrière, Paris, France
Hepatology 49:436-42. 2009..Conclusions: HIV-infected patients on combined antiretroviral therapy with chronic transaminase elevation of unknown origin have a high rate of liver lesions, mostly consistent with NASH related to insulin resistance...
Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infectionBertrand Nalpas
Unité d Hépatologie, Institut National de la Sante et de la Recherche Medicale, U567, Hopital Cochin, Paris, France
Gut 59:1120-6. 2010..Only a minority of patients with chronic hepatitis C virus (HCV) infection develops severe liver fibrosis, a process that may be controlled by human genetic factors...
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) TrialVlad Ratziu
Universite Pierre et Marie Curie Paris VI, Assistance Publique Hopitaux de Paris, Service d Hepatogastroenterologie, Paris, France
Gastroenterology 135:100-10. 2008..Nonalcoholic steatohepatitis (NASH) is a liver disease that complicates insulin-resistant states. This trial tested the efficacy and safety of rosiglitazone, an insulin-sensitizing agent, in patients with NASH...
Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposureVincent Di Martino
Service d Hepato Gastroenterologie, GH Pitié Salpétrière, Paris, France
Hepatology 40:1426-33. 2004..Pregnancies may have a beneficial impact on the long-term progression of liver fibrosis...
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosisDidier Lebrec
INSERM, Unité 773, Centre de Recherche Biomédicle Bichat Beaujon CRB3, Paris, France and Service d Hépatologie, Hopital Beaujon, Clichy, France
Gastroenterology 138:1755-62. 2010..We performed a randomized, placebo-controlled, double-blind trial of its effects in patients with cirrhosis...
Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort studyHelmi M'Kada
Service de Biochimie Métabolique, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
PLoS ONE 7:e42418. 2012..Identification of drug-induced liver disease (DILI) is difficult, even among hospitalized patients. The aim of this pilot study was to assess the impact of a specific strategy for DILI screening...
Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina FasoPhilippe Bonnard
Maladies Infectieuses, Hopital Tenon, UPMC Univ Paris 06, UPMC Paris Liver Center, Paris, France
Am J Trop Med Hyg 82:454-8. 2010..This study shows that the results of alternative methods concord with those of histology in HBV-infected patients in Burkina Faso. These alternative techniques could help physicians to identify patients requiring treatment...
What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI)Helmi M'Kada
Assistance Publique Hôpitaux de Paris UPMC Liver Center, Paris, France
Regul Toxicol Pharmacol 60:290-5. 2011..Regulatory agencies still use ULN-ALT for the definition of drug adverse events such as drug induced liver disease (DILI)...
Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case seriesHélène Prodanovic
Assistance Publique Hopitaux de Paris, Service de Pneumologie et Reanimation, Groupe Hospitalier Pitie Salpetriere, Paris, France
BMC Gastroenterol 7:2. 2007..Liver failure has been suspected to be a risk factor for aspergillosis...
Treatment of hepatitis C virus: the first decadeThierry Poynard
Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
Semin Liver Dis 24:19-24. 2004..Pegylated interferons used alone or in combination with ribavirin provide improved treatment options for different patient groups with chronic hepatitis C...
Fat, diabetes, and liver injury in chronic hepatitis CVlad Ratziu
Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
Curr Gastroenterol Rep 6:22-9. 2004..Exciting new data are expanding our understanding of the mechanisms of steatogenesis in HCV infection and providing potential links between insulin resistance or hyperglycemic states and liver fibrogenesis...
Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variantsOlivier Lada
Departments of Virology, Hepato-Gastro-Enterology, AP-HP Pitie-Salpetriere Hospital, Paris, France
J Virol 80:2968-75. 2006..The consequences of this selection process with regard to vaccine efficacy, diagnosis, and clinical evolution remain partially unknown...
Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virusDamien Sene
Department of Internal Medicine, , Paris, France
J Rheumatol 31:2199-206. 2004..Symptomatic persistent HCV MC was associated with advanced age, longer duration of HCV infection, type II MC, and a higher MC serum level...
The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIVHeidi Hannon
Nephrology Department, , Paris, France
Nephrol Dial Transplant 19:386-90. 2004..CONCLUSIONS: Our study shows that ADV dosed at 10 mg/day for the treatment of LAM-resistant chronic hepatitis B in patients co-infected with HIV is not associated with renal tubular dysfunction or a significant change in renal function...
Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infectionMichal Abel
INSERM, U561 Equipe AVENIR, Paris, France
Hepatology 44:1607-16. 2006..Therapeutic modulation of the intrahepatic balance between specific and bystander CD8 T cells might be beneficial in patients with chronic hepatitis C...
Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failureDominique Thabut
AP HP Service d Hépato Gastroentérologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
Hepatology 46:1872-82. 2007..This suggests that preventing and treating SIRS could decrease mortality in patients with cirrhosis and acute renal failure...
FAS promoter polymorphisms correlate with activity grade in hepatitis C patientsDorian McIlroy
Laboratoire d Immunologie Cellulaire et Tissulaire bService de Gastroentérologie, Hopital Pitie Salpetriere, Paris, France
Eur J Gastroenterol Hepatol 17:1081-8. 2005..Hepatocytes are susceptible to FAS-mediated apoptosis. The impact of polymorphisms in the FAS gene on histopathological features of HCV infection was therefore investigated...
Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosisThierry Poynard
Service d Hepato Gastroenterologie, Groupe Hospitalier Pitié Salpêtrière AP HP, University Paris 6, Paris, France
Antivir Ther 15:281-91. 2010..Incorporation of appropriately validated non-invasive assessments of liver fibrosis will likely improve the clinical care of patients with HCV infection...
Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood testsOlivier Lucidarme
Radiology Department, Pitie Salpetriere Hospital, Assistance Publique Hôpitaux de Paris and Université Paris 6 Pierre et Marie Curie, Paris, France
Eur J Radiol 81:1413-9. 2012..To assess the cost-effectiveness of three colorectal-cancer (CRC) screening strategies in France: fecal-occult-blood tests (FOBT), computed-tomography-colonography (CTC) and optical-colonoscopy (OC)...
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infectionEtienne Patin
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Necker Medical School, INSERM Unité 980, Paris, France
Gastroenterology 143:1244-52.e1-12. 2012..Only a fraction of patients with chronic HCV infection develop liver fibrosis, a process that might also be affected by genetic factors. We performed a 2-stage GWA study of liver fibrosis progression related to HCV infection...
Portal lymphocytic infiltrate in alcoholic liver diseaseMagali Colombat
Service Central d'Anatomie Pathologique, , Paris, France
Hum Pathol 33:1170-4. 2002..These results suggest that lymphocytes may play a role in the pathogenesis of alcohol-induced liver fibrosis...
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis CRobert P Myers
Department of Hepato-Gastroenterology, , Paris, France
Am J Gastroenterol 97:2419-25. 2002..This index is more accurate than an index of historical features, the addition of which to the existing index was not helpful...
Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferredArnaud Galbois
Universite Pierre et Marie Curie, Service d Hepato Gastroenterologie, Hôpital de la Pitié Salpêtrière AP HP, Paris, France
J Hepatol 52:839-45. 2010....
Hirsch index and truth survival in clinical researchThierry Poynard
University Pierre et Marie Curie Assistance Publique Hôpitaux de Paris Liver Center, Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
PLoS ONE 5:e12044. 2010..We hypothesized that publications with a first author having a higher Hirsch' index value (h-I), which quantifies and predicts an individual's scientific research output, should have a longer half-life...
Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalitiesGeorgia Malamut
Hepatology and Gastroenterology Department, Hopital Europeen Georges Pompidou, Paris, France
J Hepatol 48:74-82. 2008..Liver lesions associated with primary hypogammaglobulinemia have been poorly described. We aimed to assess the clinical, histological and immune features and outcome of hepatic injury in patients with primary hypogammaglobulinemia...
Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedulesJulien Taieb
Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
Cancer 98:2664-70. 2003..Therefore, the authors evaluated the activity and toxicity of two such combinations in patients with HCC...
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis CThierry Poynard
Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
Hepatology 38:75-85. 2003..In conclusion, sustained disappearance of the virus is associated with reduction of steatosis in genotype 3 as well as a correction of baseline low serum cholesterol...
Recombinant activated factor VII in chronic liver diseases: should we be afraid of thromboembolic events?Dominique Thabut
Universite Pierre et Marie Curie, Service d Hepato Gastroenterologie, Hôpital de la Pitié Salpêtrière AP HP, Paris, France
J Hepatol 55:483-5. 2011
Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?Vlad Ratziu
Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, INSERM UMRS_893, CdR Saint Antoine, Paris, France
Biomark Med 3:353-61. 2009..A noninvasive diagnosis of NASH would facilitate screening and monitoring of populations at risk, as well as the conduct of therapeutic trials...
Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitisJulien Taieb
Hepatology Department, Pitie Salpetriere Hospital, 47, Boulevard de l Hopital, 75651, Cedex 13, Paris, France
J Hepatol 36:342-8. 2002..As AH is accompanied by inflammation, neutrophilia and polymorphonuclear neutrophil (PMN) infiltration of the liver, we postulated that PMN could be a source of HGF in such patients...
Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitisDamien Sene
Department of Internal Medicine, La Pitie Salpetriere Hospital, France
Clin Biochem 39:715-21. 2006..We assessed the reliability of non-invasive biological scoring indexes (Fibrotest-Actitest [FT-AT], Forns, APRI, age-platelet, platelet, hyaluronic acid) as non-invasive alternatives to liver biopsy (LB) in 138 HCV-infected patients...
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?Thierry Poynard
Gastroenterology 128:1146-8; author reply 1148. 2005
FibroMAX: towards a new universal biomarker of liver disease?Rachel Morra
Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
Expert Rev Mol Diagn 7:481-90. 2007..The possible causes of false-negative and false-positive results are also better identified. These tests, which are now available in 50 countries, can facilitate the screening and management of the most frequent liver diseases...
[Non invasive markers using for the assessment of fibrosis in hepatitis C]Jean Pierre Zarski
Clinique universitaire d hepato gastroentérologie, pôle DIGI DUNE, Unité INSERM U 548, CHU de Grenoble, Grenoble Cedex 9
Gastroenterol Clin Biol 31:4S34-9. 2007..Diagnostic accuracy is improved by the using of all the markers, especially of Fibrotest. Transient elastography is also a promising method for assessing the severity of cirrhosis...
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver diseaseDominique Thabut
Department of Hepato-Gastroenterology, , , 75651 CNRS UMR 8149, Paris Cedex 13, France
J Hepatol 44:1175-85. 2006..CONCLUSIONS: In heavy drinkers, AshTest is a simple and non-invasive quantitative estimate of alcoholic hepatitis. The use of AshTest may reduce the need for liver biopsy, and therefore allow an earlier treatment of alcoholic hepatitis...
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver diseaseSylvie Naveau
Department of Hepato-Gastroenterology, , Clamart, France
Clin Gastroenterol Hepatol 3:167-74. 2005..CONCLUSIONS: In heavy drinkers, FT is a simple and noninvasive quantitative estimate of liver fibrosis. The use of FT may decrease the need for liver biopsy examination...
FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?Thierry Poynard
Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
Expert Rev Mol Diagn 5:15-21. 2005..The possible causes of false negatives and positives are also better identified. These tests, which are now available in 12 countries, can facilitate the screening and management of the most frequent liver diseases...
Noninvasive prediction of fibrosis in patients with chronic hepatitis CDominique Thabut
Hepatology 37:1220-1; author reply 1221. 2003
[Non-alcoholic steatosis: limits of current knowledge and lessons for hepatologists]Vlad Ratziu
Gastroenterol Clin Biol 27:715-7. 2003
NASH: a hidden and silent fibroser finally revealed?Vlad Ratziu
J Hepatol 42:12-4. 2005
Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infectionLaurent Vallat
Department of Hematology, Assistance Publique Hopitaux, , , 75651 Paris Cedex 13, France
Arthritis Rheum 50:3668-78. 2004..A high percentage of patients with B cell clonality in both the blood and liver were finally diagnosed as having a definite B cell malignancy...
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirinJohn G McHutchison
Division of Gastroenterology Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road N203, La Jolla, CA 92037, USA
Hepatology 35:688-93. 2002..In conclusion, measurement of hepatic HCV RNA before or after therapy reflects changes observed in serum HCV RNA, and correlates inversely with hepatic inflammation and fibrosis, but otherwise has minimal clinical use...
Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteriaGilles Bommelaer
Service d Hepato Gastroenterologie, hôpital de l Hôtel dieu, Clermont Ferrand
Gastroenterol Clin Biol 28:554-61. 2004....
The elusiveness of "normal" ALT in fatty liverVlad Ratziu
Hepatology 39:1172; author reply 1173. 2004
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis CSophie Le Calvez
Hepatology 39:862-3; author reply 863. 2004
Fibrogenic impact of high serum glucose in chronic hepatitis CVlad Ratziu
Service d Hepatogastroenterologie, Hopital Pitie Salpetriere, 47 83 Bd de l Hopital, Paris 75013, France
J Hepatol 39:1049-55. 2003..We tested the hypothesis that high serum glucose and overweight might contribute to this variability...
[Hepatocellular carcinoma and non alcoholic steatohepatitis: are we looking at the tip of the iceberg?]Vlad Ratziu
Service Hepatogastroenterologie, Hopital Pitie Salpetriere, Paris
Gastroenterol Clin Biol 27:869-75. 2003
[Should we have the courage to say no to systematic liver biopsy?]Thierry Poynard
Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS UPRESA 8067, 75651, Paris Cedex 13
Gastroenterol Clin Biol 27:844-6; author reply 846. 2003
Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin levelValerie Boige
Gastrointestinal Oncology Unit, Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
Eur J Cancer 42:456-9. 2006..51 and 3 ULN. However, the antitumour activity of single agent CPT-11 was not significant in advanced HCC...
Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative studyPierre Pradat
Department of Hepatology, , Lyon, France
Hepatology 36:973-7. 2002..In this subset of patients, the indication of liver biopsy and the potential benefit of therapy need to be further evaluated. These results suggest the need to revisit the algorithm for liver biopsy practice...
Diagnostic value of FibroTest with normal serum aminotransferasesThierry Poynard
Hepatology 43:374-5; author reply 375-6. 2006
Meta-analyses of FibroTest diagnostic value in chronic liver diseaseThierry Poynard
Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
BMC Gastroenterol 7:40. 2007....
High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic ratsDominique Thabut
INSERM, U773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Paris 75018, France
Hepatology 46:1893-906. 2007..This suggests that the decrease in circulating HDL in cirrhosis plays a role in the excessive proinflammatory response and intrahepatic eNOS down-regulation...
FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis CRachel Morra
Hepatology 47:353-4; author reply 354-6. 2008
Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis CMaria Alessandra Rosenthal-Allieri
Laboratoire central d immunologie, CHU de Nice, Hopital de l Archet, Nice Université de Nice Sophia Antipolis, 151 route Saint Antoine de Ginistière, Nice
Gastroenterol Clin Biol 31:815-21. 2007..The aims of this study were to evaluate the analytical variability of the Fibrotest-Actitest proteins alpha 2-macroglobulin, haptoglobin and apolipoprotein-A1, and to assess their impact on the Fibrotest-Actitest scores...
Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markersMireen Friedrich-Rust
Department of Internal Medicine, JW Goethe University Clinic, Frankfurt, Germany
J Thorac Cardiovasc Surg 135:560-7. 2008..Therefore, early detection of fibrosis is essential to identify patients at risk. Transient elastography has been evaluated for noninvasive staging of liver fibrosis in a multitude of studies...
Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizationsMona Munteanu
Clin Biochem 41:1113-4. 2008
Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis CRobert P Myers
Department of Medicine, University of Calgary, Calgary, Canada
Can J Gastroenterol 21:289-94. 2007..The objective of the present study was to determine the clinical and histological correlates of serum leptin in HCV-infected patients, and to determine its utility in predicting liver histological lesions...
Discussion on celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failureVlad Ratziu
Gastroenterology 123:2158-9; author reply 2159-60. 2002
[Can metabolic steatohepatitis be treated?]Vlad Ratziu
Groupe Hospitalier Pitié Salpêtrière et Université Pierre et Marie Curie, Paris
Gastroenterol Clin Biol 31:333-40. 2007
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infectionLaurent Alric
Service de Medecine Interne, Pavillon Dieulafoy, CHU Purpan, Toulouse, France
Gastroenterology 123:1494-9. 2002....
Assessing the outcome of nonalcoholic steatohepatitis? It's time to get seriousVlad Ratziu
Hepatology 44:802-5. 2006
